Rosin Miriam P, Poh Catherine F, Guillard Martial, Williams P Michele, Zhang Lewei, MacaUlay Calum
BC Oral Cancer Prevention Program, BC Cancer Agency, Cancer Control Research Centre, Vancouver, BC, Canada.
Ann N Y Acad Sci. 2007 Mar;1098:167-83. doi: 10.1196/annals.1384.039. Epub 2007 Mar 1.
The genomic era has fueled a rapid emergence of new information at the molecular level with a great potential for developing innovative approaches to detection, risk assessment, and management of oral cancers and premalignant disease. As yet, however, little research has been done on complementary approaches that would use different technology in conjunction with molecular approaches to create a rapid and cost-effective strategy for patient assessment and management. In our ongoing 8-year longitudinal study, a set of innovative technologies is being validated alone and in combination to best correlate with patient outcome. The plan is to use these devices in a step-by-step sequence to guide key clinicopathological decisions on patient risk and treatment. The devices include a hand-held visualization device that makes use of tissue autofluorescence to detect and delineate abnormal lesions and fields requiring follow-up, to be used in conjunction with optical contrast agents such as toluidine blue. In addition, two semi-automated high-resolution computer microscopy systems will be used to quantitate the protein expression phenotype of cell nuclei in tissue sections and exfoliated cell brushings. Previously identified risk-associated molecular changes are being used to validate these systems as well as to establish their place in a population-based triage program that will filter out high-risk cases in the community and funnel them to dysplasia clinics where higher-cost molecular tools will guide intervention. A critical development for the translation of this technology into community settings is the establishment of an effective methodology for education and training of health practitioners on the front lines.
基因组时代推动了分子水平新信息的迅速涌现,为开发口腔癌及癌前病变的检测、风险评估和管理创新方法带来了巨大潜力。然而,目前对于将不同技术与分子方法结合使用以创建快速且具成本效益的患者评估和管理策略的互补方法,研究甚少。在我们正在进行的为期8年的纵向研究中,一组创新技术正在单独和联合进行验证,以使其与患者预后最佳关联。计划是按步骤依次使用这些设备,以指导有关患者风险和治疗的关键临床病理决策。这些设备包括一种手持式可视化设备,它利用组织自发荧光来检测和描绘需要随访的异常病变及区域,并与诸如甲苯胺蓝等光学造影剂联合使用。此外,两个半自动高分辨率计算机显微镜系统将用于定量组织切片和脱落细胞刷片中细胞核的蛋白质表达表型。先前确定的与风险相关的分子变化正用于验证这些系统,并确定它们在基于人群的分流计划中的地位,该计划将筛选出社区中的高危病例,并将其引导至发育异常诊所,在那里更高成本的分子工具将指导干预。将该技术转化至社区环境的一个关键进展是建立一种有效的方法,用于对一线卫生从业者进行教育和培训。